• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

    8.515 +0.045 (+0.54%)
    Streaming Delayed Price Updated: 2:46 PM EDT, Oct 22, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Amicus Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    This CSX Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
     
    Via Benzinga
    New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM
    Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® 
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Earnings Scheduled For July 31, 2025
     
    Via Benzinga
    Earnings Scheduled For May 1, 2025
     
    Via Benzinga
    Amicus Therapeutics Earnings Preview
     
    Via Benzinga
    Earnings Scheduled For February 19, 2025
     
    Via Benzinga
    A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts
     
    Via Benzinga
    Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
    Via Investor Brand Network
    Topics Government
    Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
    EQNX::TICKER_START (NASDAQ:SNGX),(NASDAQ:FOLD),(NASDAQ:TNXP),(NASDAQ:CTOR),(NASDAQ:AMGN) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Government
    Amicus (FOLD) Q2 Revenue Jumps 22%
    Via The Motley Fool
    Topics Intellectual Property
    Amicus Therapeutics Inc (NASDAQ:FOLD) Beats Q2 2025 Earnings and Revenue Estimates, Shares Rise in Pre-Market Trading
    Amicus Therapeutics (FOLD) beats Q2 2025 revenue and EPS estimates, driven by strong growth in Galafold and Pompe disease therapies, sparking a 2.77% pre-market rally. 
    Via Chartmill
    Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
    Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD) 
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
     
    Via Benzinga
    Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
    From Amicus Therapeutics, Inc.; Dimerix Limited
    Via GlobeNewswire
    Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm
    From Kaskela Law LLC
    Via Business Wire
    Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
    Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.